WO1989005642A1 - Potentialisateur de dextrorphane pour compositions antispasmodiques et procedes - Google Patents

Potentialisateur de dextrorphane pour compositions antispasmodiques et procedes Download PDF

Info

Publication number
WO1989005642A1
WO1989005642A1 PCT/US1988/004539 US8804539W WO8905642A1 WO 1989005642 A1 WO1989005642 A1 WO 1989005642A1 US 8804539 W US8804539 W US 8804539W WO 8905642 A1 WO8905642 A1 WO 8905642A1
Authority
WO
WIPO (PCT)
Prior art keywords
anticonvulsant
dextromethorphan
metabolite
dextrorphan
pharmaceutical composition
Prior art date
Application number
PCT/US1988/004539
Other languages
English (en)
Inventor
John W. Ferkany
Michael J. Pontecorvo
Original Assignee
Ferkany John W
Pontecorvo Michael J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferkany John W, Pontecorvo Michael J filed Critical Ferkany John W
Priority to JP89501353A priority Critical patent/JPH02502546A/ja
Publication of WO1989005642A1 publication Critical patent/WO1989005642A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Definitions

  • the present invention relates to a novel composition and a method for the treatment of epilepsy and other forms of convulsions. More specifically, the invention is directed to a pharmaceutical composition comprising the metabolites of dextromethorphan as a potentiating agent for an anticonvulsant drug.
  • DPH diphenylhydantoin
  • Phenytoin stems from its ability to Inhibit epileptic activity without causing a general depression of the central nervous system. Phenytoin also has the advantage in that it can limit the development of maximal seizure activity and reduce the spread of the seizure process from an active focus.
  • the dose-dependent toxic effects associated with the continued use of phenytoin as well as other anticonvulsant hydantoins include cerebellar vestibular effects (nystagmus, ataxia and diplopia vertigo) and central nervous system disturbances such as blurred vision, mydriasis and hyperactive tendon reflexes.
  • Behavioral changes that have been associated with the use of phenytoin include hyperactivity, confusion, dullness, drowsiness and hallucination.
  • Further adverse toxic effects include increased frequency of seizures, peripheral neuropathy, gastrointestinal distress, gingival hyperplasia, osteomalacia, megaloblastic anemia, hirsutism, endocrine effects and lymphadenopathy.
  • phenytoin can cause cardiovascular collapse and depression of the central nervous system.
  • Tortella showed that 30 mg/kg dextromethorphan administered s.c. to rats could provide complete protection against transauricular maximal electroshock seizures.
  • the anticonvulsant potency of phenytoin was potentiated by co-administration of dextromethorphan and that this potentiating effect was present even at sub-threshold levels of dextromethorphan (e.g., 15 rag/kg s.c).
  • Tortella was based, in part, on earlier findings reported by Craviso and Musacchio in Mol. Pharmacol.. 23:619-628 and 23:629-640 (1983). This study was conducted in part to determine whether dextro ⁇ methorphan binds at a subset of opiate receptors. Craviso and Musacchio demonstrated high affinity binding of [ 3 H]dextromethorphan to homogenates of guinea pig, mouse and rat lower brainstem (K ⁇ less than 20 nM) .
  • Tortella and Musacchio U.S. Patent No. 4,694,010 of the potentiating characteristics of dextromethorphan as an anticonvulsant was based on the binding site of [ 3 H]dextromethorphan, and on the compounds, like dextromethorphan, which inhibited binding at the same site at concen ⁇ trations considered reasonable to those skilled in the art (IC50 ⁇ 500 nM) .
  • Tortella and Musacchio were, however, rather narrow since I R]dextromethorphan and the related non-opiate compounds were believed to be able to potentiate only the anti-epileptic hydantoin anticonvulsants which enhanced binding to the dextromethorphan site in the central nervous system.
  • anticonvulsants such as carbamazepine, phenobarbital, diazepam and ketamine which were specifically shown not to Inhibit or enhance [ • ]dextromethorphan binding.
  • potentiating compounds were also limited by the require ⁇ ments that the potentiators are non-opioid compounds that act at the same binding site as dextromethorphan. Thus, related compounds that do not inhibit or enhance [ ** ⁇ ]dextromethorphan binding were excluded.
  • dextromethorphan is rapidly metabolized in vivo via oxidative O-demethylation to yield dextrorphan (DEX) and two lesser metabolites.
  • the minor N- and N,O-demethylation metabolite products are (+) D-(3) methoxymorphinan and (+) D-hydroxymorphinan respectively.
  • the absolute plasma levels of dextro ⁇ methorphan following administration of 20 to 60 mg p.o. in humans rarely exceeds five nanograms per milliliter whereas the dextrorphan levels are 380 nanograms per milliliter.
  • dextrorphan represents the major metabolite since, in eight hours, the other demethylation products in urine account for less than 15% of the dose of dextromethorphan administered. More importantly, the major metabolite, dextrorphan, has a relatively low affinity (> 2000 nM) for the [ ** ⁇ ]dextromethorphan receptor but a relatively high affinity for the [ 3 H]TCP-labeled-NMDA-linked receptor ( ⁇ 10 nM) .
  • dextromethorphan is rapidly converted to dextrorphan jLn vivo these data raise the possibility that dextromethorphan's anticonvulsant effects may not be directly related to the [ 3 H]dextromethorphan binding site as suggested by Tortella and Musacchio, but may result from the action of metabolites at other (e.g., PCP/NMDA) receptors.
  • PCP/NMDA PCP/NMDA
  • the present invention is directed primarily to the discovery that the metabolites of dextromethorphan which do not bind with reasonable affinity at the dextromethorphan receptor site (IC50 > 100 nM) can act as an effective potentiator for anticonvulsants, including both those like phenytoin, chat enhance [ K]dextromethorphan binding and those that do not inhibit or enhance [*- ⁇ ]dextromethorphan binding (e.g., carbamazepine, phenobarbital, diazepam, ketamine) .
  • the present invention relates to a composition of matter and a method of treating epilepsy using the metabolite of dextromethorphan as a potentiating agent for anticonvulsants.
  • the present invention is directed primarily to a composition of matter including at least one metabolite of dextromethorphan as a pote ⁇ tiator for an anticonvulsant agent. More particularly the invention relates to a pharmaceutical composition which utilizes the metabolites of dextromethorphan as the potentiating agent for any anticonvulsant. The invention further relates to a method of treating epilepsy using the composition including an effective amount of potentiating agent of one of the metabolites of dextromethorphan and an anticonvulsant agent.
  • the present invention is directed to the discovery that the metabolites of dextromethorphan and In particular the major metabolite, dextrorphan, are useful as anticonvulsants in the treatment of epilepsy. Moreover, the present invention relates to the discovery that the metabolites of dextro ⁇ methorphan are effective potentiating agents for other anticonvulsant compounds. Specifically the metabolites of dextromethorphan have been shown to potentiate and increase the effectiveness of anticonvulsants and also to interact with PCP-linked-NMDA receptors.
  • the dextromethorphan metabolite is intermixed in a potentiating amount, or administered separately as an adjunct, with a suitable anticonvulsant.
  • the compounds are introduced to the patient in an amount necessary to treat epilepsy and prevent or control convulsions.
  • Dextromethorphan [(+) 3-methoxy-17-methylmorphinan] is a widely used non- opiate antitulich which has recently been shown to possess anticonvulsant activity against electrical seizure in laboratory animals.
  • Dextromethorphan is known to have has a high affinity for the [ ** ⁇ ]dextromethorphan labeled receptor but a relatively low affinity for the PCP receptor sites.
  • Dextromethorphan when introduced to the human body rapidly metabolizes into three metabolites.
  • the major O-demethylated metabolite is dextrorphan (DEX) , D(+)-17-methylmorphinan-3-ol.
  • the minor metabolites by the N, and N,0-deraethylation process are (+)D-3 methoxymorphinan, and (+)D- hydroxymorphinan.
  • Dextrorphan demonstrates a low affinity for the [ 3 H]dextromethorphan receptor (IC 50 - 140 - 5000 nM) but a very high affinity for the PCP-labeled NMDA-linked receptor (IC50 ⁇ 10 nM) . Since dextrorphan functions by a different mechanism, and binds at different sites than dextromethorphan, dextrorphan provides an additional approach to control and prevent convulsions in patients affected with seizure disorders. Additionally, we have discovered that dextrorphan can be used in a manner by which the anticonvulsant properties of other anticonvulsants can be improved or potentiated at lower dosages thereby providing a lowering of the chronic toxicity of the drugs.
  • anticonvulsants examples include phenytoin, amobarbital sodium (sodium 5-ethyl-5-isopentylbarbiturate) , methsuximide (N,2-Dimethyl-2-phenylsuccinimide), clonazepam (5-(2 chloro ⁇ henyl)-l, 3- dihydro-7-nitro 2H-1.4, benzodiazepine-2-one) , valproic acid, metharbital (5,5 diethyl-1-methylbarbituric acid), mephobarbital (5-ethyl-l-methyl-5- phenylbarbituric acid, ephenytoin (3-methyl 5,5-phenyl-ethyl-hydantoin) , primidone, paramethadione (5-ethyl-3,5-demethyl-2,4-oxazolidinedione, phenacemide (N-aminocarbonyl)-benzeneacetamide,
  • the preferred anticonvulsants according to the invention are phenytoin or carbamazepine. It has been discovered that by simultaneously administering these different types of anticonvulsants with the metabolites of dextro ⁇ methorphan the effects of the anticonvulsants can be potentiated to reduce the required amount for effective treatment.
  • Ethosuximide was determined to be ineffective in protecting against these seizures since only one in five mice was protected at one half hour and none was protected one hour after i.p. injections of 500 mg/kg. At this dose all mice injected showed signs of sedation, ataxia and gross toxicity.
  • the first study compared the effects of dextrorphan, dextromethorphan and phenytoin.
  • Dextrorphan and dextromethorphan were dissolved in saline.
  • Phenytoin was dissolved in 30% propylene glycol in distilled water.
  • Dextrorphan and dextromethorphan were administered 30 min and phenytoin 1 hr prior to the MES test. . All injections were i.p. in a volume of 0.01 ml/g.
  • Dextrorphan like phenytoin and dextromethorphan, is shown in Table 1 to be a potent and efficacious anticonvulsant against MES seizures.
  • the anticonvulsant effects of the dextrorphan were dose-related having an ED50 of 12.7 mg/kg. At higher doses, dextrorphan decreased the incidence of tonic hindlimb extension to 0%. When compared on the basis of molecular weight, dextrorphan was 2.2 times more potent than dextromethorphan as an anticonvulsant against MES seizures.
  • mice Based on at least 8 doses for each drug, covering the entire range from 0 to 100% protection, n > 8 mice per dose. Values in parenthesis are 95% confidence limits calculated according to the method of Litchfield and Wilcoxon (1949, J. Pharmacol. EXP. Thera .. 49:99). All values are reported as mg/kg.
  • mice Male CF-1 mice weighing 25 - 30 grams were used for all studies. All of the test animals were naive to drug and seizure exposure and were used only once. Compounds of interest were dissolved in saline (0.9%; w/v) and administered i.p. in a final volume of 1 percent of body weight. Test compounds (anticonvulsants) were administered 30 minutes prior to the induction of seizures. Seizures were induced by the administration of NMDA (250 mg/kg) and animals were observed for a period of thirty minutes. Typically, control animals responded with seizure activity consisting of initial staring followed in rapid order by hindlimb scratching, increased locomotor activity, rearing behavior, clonic seizures, tonic extension and death.
  • NMDA 250 mg/kg
  • M 801 was the most effective compound evaluated to antagonize NMDA-induced seizures and, on a mole basis was 7-fold more potent than PCP.
  • the order of potency of the remaining compounds was PCP > 3-(2- carboxypiperazin-4-yl)propyl-l-phosphonic acid (CPP) > ketamine - dextrorphan
  • dextromethorphan > DL( ⁇ )2-amino-7-phosphonoheptanoic acid (AP7) .
  • AP7 DL( ⁇ )2-amino-7-phosphonoheptanoic acid
  • NMDA receptor antagonist AP7.
  • PCP phencyclidine
  • CPP 3-(2 carboxy-piperazin- 4-yl)propyl-l-phosphono acid
  • KET ketamine
  • DEX dextrorphan
  • DM dextromethorphan.
  • GABA ⁇ receptor agonists muscimol 5 mg/kg and THIP (15 mg/kg), the GABA ⁇ receptor agonist, baclofen (20 mg/kg), as well as the antlcholinerglc, atropine sulfate (10 mg/kg).
  • Other compounds which inhibit seizures but were not able to inhibit NMDA- induced convulsions were two antitussives agents including the dextro ⁇ methorphan receptor active agents, caramiphen (100 - 500 mg/kg) and noscapine (100 - 400 mg/kg).
  • dextrorphan was examined using the MES seizure model described in Example I, above.
  • Male CF-1 mice weighing approximately 27-34 grams were randomly assigned to control or drug treatment groups. All of the test animals were naive to drug and seizure exposure and used only once.
  • Dextrorphan was dissolved in saline and phenytoin in 30% propylene glycol in distilled water as described above. For combination studies phenytoin was administered 1 hr and dextrorphan 30 min prior to the test.
  • Table 3 shows that dextrorphan potentiated the anticonvulsant effects of phenytoin.
  • the amount of protection (% animals without seizures) at any given dose of phenytoin was increased by co-administration of dextrorphan.
  • 9 mg/kg dextrorphan (a dose marginally effective when administered alone) increased the % protection from 0 to 37.5 at 0.25 mg/kg phenytoin, from 4.2 to 50 at 1 mg/kg phenytoin, and from 8.3 to 100 at 3.5 mg/kg phenytoin.
  • the median effective dose (ED50) of phenytoin was decreased almost 7-fold from 5.5 to 0.81 mg/kg.
  • the foregoing examples demonstrate that the dextromethorphan metabolite dextrorphan is a potent anticonvulsant when administered alone in both the MES and N-methyl-D-aspartate models, and effectively potentiates the anticonvulsant effects of phenytoin in the MES model.
  • dextromethorphan metabolites may also be effective anticonvulsants, regardless of whether they compete at dextromethorphan receptors, and also suggests that the range of anticonvulsants that can be potentiated by dextromethorphan or its metabolites may include compounds like carbamazepine that do not interact with dextromethorphan receptors.
  • a metabolite of dextro ⁇ methorphan is administered as the potentiating agent with an anticonvulsant drug.
  • an anticonvulsant drug Any anticonvulsant may be used but phenytoin or carbamazepine are preferred.
  • simultaneous administration in one dosage form is preferred, the compounds may be introduced sequentially or in any order necessary to achieve the optimal control of seizures.
  • the preferred form of administration is oral but any medically accepted route of administration may be employed.
  • the novel composition according to the present invention is used primarily for treatment of convulsions and in particular epilepsy.
  • at least one of the metabolites of dextromethorphan is combined with an anticonvulsant in a proportion whereby the effectiveness of the anticonvulsant is potentiated.
  • potentiating the anticonvulsant effects the amount of the anticonvulsant can be reduced which reduces the dose-related side effects associated with continued use of standard anti ⁇ convulsants without sacrificing the efficacy.
  • the type and severity of the convulsions experienced by the patient will determine the amount of the combination administered.
  • the ratio of the potentiating agent to the anticonvulsant and the effectiveness of the anticonvulsant will determine the amount and form of the composition to be administered to the patient.
  • the form of the anticonvulsants according to the present invention can be a liquid oral dose in the form of solutions and suspensions.
  • the active ingredients are generally dissolved or suspended in distilled water containing a small amount of alcohol to facili ⁇ tate suspension.
  • conventional syrup formulations or any other pharmaceutically acceptable liquid carrier may be employed.
  • parenteral administration is the preferred method of introducing the anticonvulsants to the patient the compounds are dissolved in a suitable liquid carrier.
  • suitable liquid carrier is polyethylene glycol and alcohol although others may be used which are known by those skilled in the art.
  • the anticonvulsants may be introduced as an oral dose in a solid form such as a tablet, pill or capsule.
  • the tablets or capsules may be coated as desired to allow the tablets to be easily swallowed and to provide flavoring.
  • Coatings commonly employed in the pharmaceutical industry may be applied from aqueous suspensions of sugar and insoluble powders such as starch, calcium carbonate, talc and titanium dioxide suspended with a suitable mixing agent such as gelatin. Additional coatings may be applied as desired including water soluble dispersible material such as hydroxy- methylcellulose, cellulose, methylcellulose, carboxymethyl cellulose and mixtures of cellulose acetate and polyethylene glycol.
  • the suitable dosage form may be a capsule formed from commonly employed materials.
  • the components are generally compounded with inert fillers such as talc, lactose, starch, bentonite, diatomaceous earth, lubricants and food flavorings.
  • inert fillers such as talc, lactose, starch, bentonite, diatomaceous earth, lubricants and food flavorings.
  • the tablets are generally formed by conventional procedures including compression molding.

Abstract

Une composition pharmaceutique comprend un médicament actif antispasmodique et une quantité efficace d'au moins un métabolite de dextrométhorphane, suffisante pour potentialiser l'effet antispasmodique du médicament antispasmodique. Ces métabolites, en particulier le dextrorphane, potentialisent efficacement l'effet d'antispasmodiques, y compris de la phénytoïne et de la carbamazépine. Selon un procédé de traitement de l'épilepsie et d'autres formes de convulsions, on administre simultanément ou successivement une quantité efficace du médicament antispasmodique et une quantité d'au moins un des métabolites de dextrométhorphane suffisante pour potentialiser l'action du médicament antispasmodique.
PCT/US1988/004539 1987-12-22 1988-12-19 Potentialisateur de dextrorphane pour compositions antispasmodiques et procedes WO1989005642A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP89501353A JPH02502546A (ja) 1987-12-22 1988-12-19 抗ひきつけ剤組成物および方法のためのデキストロルファン相乗的協力剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13656487A 1987-12-22 1987-12-22
US136,564 1987-12-22

Publications (1)

Publication Number Publication Date
WO1989005642A1 true WO1989005642A1 (fr) 1989-06-29

Family

ID=22473385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/004539 WO1989005642A1 (fr) 1987-12-22 1988-12-19 Potentialisateur de dextrorphane pour compositions antispasmodiques et procedes

Country Status (4)

Country Link
EP (1) EP0346445A4 (fr)
JP (1) JPH02502546A (fr)
AU (1) AU2929489A (fr)
WO (1) WO1989005642A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007447A1 (fr) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Composition contenant un anticonvulsivant destinee au traitement de la douleur nevropathique
WO1999012537A1 (fr) * 1997-09-08 1999-03-18 Warner-Lambert Company Compositions analgesiques comprenant des composes anticonvulsivants et leur mode d'utilisation
US6242488B1 (en) 1997-08-20 2001-06-05 University Of Oklahoma Method for preventing and treating pain
WO2004087161A1 (fr) * 2003-04-04 2004-10-14 Novartis Ag Combinaisons de medicaments anti-epileptiques permettant de traiter des troubles neurologiques
WO2004089352A2 (fr) * 2003-04-09 2004-10-21 Richter Gedeon Vegyészeti Gyár Rt. Combinaison pharmaceutique pour le traitement de l'hypertonie spastique et/ou la douleur
EP1471909A1 (fr) * 2002-01-16 2004-11-03 Endo Pharmaceuticals Inc. Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central
AU2002301362B2 (en) * 1997-09-08 2005-12-15 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO2014173900A1 (fr) * 2013-04-22 2014-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode et composition pharmaceutique pour l'utilisation dans le traitement de crises épileptiques
US9763954B2 (en) 2007-01-15 2017-09-19 Bial—Portela & Ca, S.A. Therapeutical uses of eslicarbazepine
US10675287B2 (en) 2005-05-06 2020-06-09 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798109A (en) * 1992-07-13 1998-08-25 Shiseido Company, Ltd. External skin treatment composition
US5686086A (en) * 1992-07-13 1997-11-11 Shiseido Co., Ltd. External skin treatment composition
US5962000A (en) * 1992-07-13 1999-10-05 Shiseido Company, Ltd. External skin treatment composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4380548A (en) * 1981-08-27 1983-04-19 Warner-Lambert Company N-(2,6-Dimethylphenyl)-4,5-dihydro-4,4-dialkyl-2-methylthio-1H-imidazole-1-carboxamides, anticonvulsive composition and method
US4694010A (en) * 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4380548A (en) * 1981-08-27 1983-04-19 Warner-Lambert Company N-(2,6-Dimethylphenyl)-4,5-dihydro-4,4-dialkyl-2-methylthio-1H-imidazole-1-carboxamides, anticonvulsive composition and method
US4694010A (en) * 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0346445A4 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187338B1 (en) 1996-08-23 2001-02-13 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US6406716B2 (en) 1996-08-23 2002-06-18 Endo Pharmaceuticals Inc. Anticonvulsant containing composition for treating neuropathic pain
WO1998007447A1 (fr) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Composition contenant un anticonvulsivant destinee au traitement de la douleur nevropathique
US6242488B1 (en) 1997-08-20 2001-06-05 University Of Oklahoma Method for preventing and treating pain
US6426368B2 (en) 1997-08-20 2002-07-30 Warner-Lambert Company Method for preventing and treating alcoholism
US6942876B2 (en) 1997-09-08 2005-09-13 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO1999012537A1 (fr) * 1997-09-08 1999-03-18 Warner-Lambert Company Compositions analgesiques comprenant des composes anticonvulsivants et leur mode d'utilisation
US6593368B2 (en) 1997-09-08 2003-07-15 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU2002301362B8 (en) * 1997-09-08 2006-05-04 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU2002301362B2 (en) * 1997-09-08 2005-12-15 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP1471909A4 (fr) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central
EP1471909A1 (fr) * 2002-01-16 2004-11-03 Endo Pharmaceuticals Inc. Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central
WO2004087161A1 (fr) * 2003-04-04 2004-10-14 Novartis Ag Combinaisons de medicaments anti-epileptiques permettant de traiter des troubles neurologiques
AU2004226825B2 (en) * 2003-04-04 2007-08-16 Novartis Ag Combinations comprising anti-epileptic drugs for the treatment of neurological disorders
WO2004089352A3 (fr) * 2003-04-09 2004-12-16 Richter Gedeon Vegyeszet Combinaison pharmaceutique pour le traitement de l'hypertonie spastique et/ou la douleur
WO2004089352A2 (fr) * 2003-04-09 2004-10-21 Richter Gedeon Vegyészeti Gyár Rt. Combinaison pharmaceutique pour le traitement de l'hypertonie spastique et/ou la douleur
EA007732B1 (ru) * 2003-04-09 2006-12-29 Рихтер Гедеон Ведьесети Дьяр Рт. Фармацевтическая комбинация для лечения мышечной спастичности и/или боли
US10675287B2 (en) 2005-05-06 2020-06-09 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate
US10695354B2 (en) 2005-05-06 2020-06-30 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate
US10702536B2 (en) 2005-05-06 2020-07-07 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate
US11364247B2 (en) 2005-05-06 2022-06-21 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate
US9763954B2 (en) 2007-01-15 2017-09-19 Bial—Portela & Ca, S.A. Therapeutical uses of eslicarbazepine
WO2014173900A1 (fr) * 2013-04-22 2014-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode et composition pharmaceutique pour l'utilisation dans le traitement de crises épileptiques

Also Published As

Publication number Publication date
AU2929489A (en) 1989-07-19
JPH02502546A (ja) 1990-08-16
EP0346445A1 (fr) 1989-12-20
EP0346445A4 (fr) 1990-03-28

Similar Documents

Publication Publication Date Title
JP4977297B2 (ja) トラマドール物質及び抗痙攣薬を含んで成る組成物
US20050038062A1 (en) Methods and materials for the treatment of pain comprising opioid antagonists
NZ509260A (en) Pharmaceutical composition containing valsartan and a calcium channel blocker
WO1989005642A1 (fr) Potentialisateur de dextrorphane pour compositions antispasmodiques et procedes
US4694010A (en) Anticonvulsant compositions and method
JP2003520234A (ja) 薬物中毒の治療方法
US5629336A (en) Use of glycine/NMDA receptor ligands for the treatment of drug dependence and withdrawal
US4906638A (en) Dextromethorphan potentiator for anticonvulsant composition and method
JP2001520989A (ja) 哺乳動物における欲求を減少する方法
US4898860A (en) Anticonvulsant composition and method
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
US20050089558A1 (en) Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
JP2003503459A (ja) パラセタモール及びブスピロンを含有した鎮痛性作用を有する新規医薬組成物
JP2000264849A (ja) 頻尿・尿失禁治療組成物
EA003557B1 (ru) Схема обезболивания
EA011926B1 (ru) Пероральный антидепрессивный состав, включающий ацетилсалициловую кислоту для ускорения начала действия
AU2004233582B2 (en) Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
CZ312894A3 (en) Use of isethionate of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for preparing a medicament used for treating and prevention of dependence, tolerance and response to drugs
JPH1129476A (ja) 麻薬依存抑制剤
EP1797883A2 (fr) Composition pharmaceutique comprenant un inhibiteur de la cathepsine S et un opiode
JPH08231399A (ja) モルヒネ禁断抑制作用剤
NZ243613A (en) Tablet comprising praziquantel, pyrantel pamoate and oxantel pamoate in synergistic proportions for treatment of nematode infestations
MXPA00004135A (en) Method of reducing craving in mammals

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989901396

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989901396

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989901396

Country of ref document: EP